Personalized Medicine in Clinical Management of Breast Cancer: Where Do We Stand?
Author:
Publisher
Springer Nature Singapore
Link
https://link.springer.com/content/pdf/10.1007/978-981-99-3746-2_28
Reference231 articles.
1. Abd-Aziz N, Kamaruzman NI, Poh CL (2020) Development of microRNAs as potential therapeutics against cancer. J Oncol 2020:8029721. https://doi.org/10.1155/2020/8029721
2. Abel AM, Yang C, Thakar MS, Malarkannan S (2018) Natural killer cells: development, maturation, and clinical utilization. Front Immunol 9:1869. https://www.frontiersin.org/article/10.3389/fimmu.2018.01869
3. Adams S, Diamond JR, Hamilton E, Pohlmann PR, Tolaney SM, Chang C-W et al (2019) Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA Oncol 5(3):334–342. https://doi.org/10.1001/jamaoncol.2018.5152
4. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS et al (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23(11):2534–2543. https://doi.org/10.1200/JCO.2005.03.184
5. Aktas B, Müller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR et al (2011) Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol 122(2):356–360. https://doi.org/10.1016/j.ygyno.2011.04.039
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3